Where are we Headed in Thyroid Cancer? New and Emerging Treatment Approaches

Released On
November 12, 2020

Expires On
October 28, 2021

Media Type
Internet

Completion Time
30 minutes

Specialty
Hematology-Oncology, Pathology, Pharmacy, Primary Care, Radiology, Surgery

Topic(s)
Oncology, Radiology, Surgery

Scroll to the Bottom of this Information to Begin this Course

Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC (PQHE) working in collaboration with the National Organization for Rare Disorders (NORD).

 

This activity is supported by educational grants from Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, LLC.; Eisai Inc.; Epizyme Inc.; Innate Pharma, Inc.; Ipsen Biopharmaceuticals, Inc.; Karyopharm Therapeutics; Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc.; Sanofi Genzyme; and Seattle Genetics, Inc.

Credit Available

  • Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)
  • Physicians — maximum of 0.5 MOC Credit
  • Physician Assistants — maximum of 0.5 CME Credit
  • Pharmacists — maximum of 0.5 Contact Hour
  • Nurses — maximum of 0.5 Contact Hour (0.50 CEUs)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for community-based and academic/specialist hematologists, medical oncologists, hematologic oncologists, pathologists, radiologic oncologists, surgical oncologists, primary care providers, oncology nurses and nurse navigators, nurse practitioners, physician assistants, and pharmacists.

Learning Objectives

At the conclusion of this activity, participants will be able to:

  • Discuss coordination of care and clinical strategies to decrease the time to diagnosis for patients with rare cancers and blood disorders
  • Integrate patient-centered and evidence-based treatment options for rare cancers and blood disorders
  • Review emerging therapies under investigation as treatment options
  • Evaluate management strategies of adverse events to improve patient outcomes
  • Facilitate informed and shared decision-making through access to disease-related and support resources

Faculty

Catherine M. Broome, MD

Associate Professor of Medicine
MedStar Georgetown University
Lombardi Cancer Center

Steven Horwitz, MD

Attending Physician
Memorial Sloan Kettering Cancer Center

Ayalew Tefferi, MD

Professor of Hematology and Internal Medicine
Division of Hematology
Mayo Clinic College of Medicine in Rochester
Minnesota

Robert J. Kreitman, MD

Hairy Cell Leukemia
Bethesda, Maryland

Jonathan C. Trent, MD, PhD

Professor of Medicine
Associate Director, Clinical Research
Leader, Sarcoma Multidisciplinary Group
Sylvester Comprehensive Cancer Center
Miller School of Medicine
University of Miami

Lori J. Wirth, MD

Elizabeth and Michael Ruane Endowed Chair of Medical Oncology
Associate Professor of Medicine, Harvard
Medical School
Medical Director, Head and Neck Oncology
Massachusetts General Hospital

Jonathan Strosberg, MD

Professor
Moffitt Cancer Center

Michael C. Heinrich, MD, FACP

Professor of Medicine
Professor of Cell, Developmental and Cancer
Biology
OHSU Knight Cancer Institute

Ghassan Abou-Alfa, MD, MBA

Professor
Memorial Sloan Kettering Cancer Center

Joint Accreditation Statement

 

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

 

Enduring Credit Designation Statements

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, MOC credit is reported on a monthly basis.

To claim and receive MOC credits, learners must provide:

  • ABIM ID number
  • First and last name
  • Degree and specialty
  • DOB (MMDD)
  • Activity completion date

AAPA Credit Designation Statement

Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until October 28, 2021. PAs should only claim credit commensurate with the extent of their participation.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008162-9999-20-2396-H01-P)Type of Activity: Application

Pharmacists will need to provide their National Association of Boards of Pharmacy (NABP) e-Profile ID and date of birth (MMDD) to ensure the data is submitted to the ACPE and NABP properly. If you need to obtain your NABP e-Profile, please visit www.nabp.net.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Date of Release/Expiration

Live Activity
Spotlight on Rare Cancers: Advancing Novel Therapy and Patient Centered Management

Wednesday, October 28, 2020 from 11:30am – 3:30pm ET: Track 1 - Rare Blood Disorders, Leukemias, and Lymphomas

  • 11:30am – 12:30pm ET: Cold Agglutinin Disease (CAD): The Role of the Complement Pathway in Treating a Rare Autoimmune Hemolytic Anemia
  • 12:30pm – 1:30pm ET: Addressing the Challenges of Peripheral T-Cell Lymphoma Management
  • 1:30pm – 2:30pm ET: Risk-Based Approach for Treatment of Myelofibrosis
  • 2:30pm – 3:30pm ET: Managing Relapsed/Refractory Hairy Cell Leukemia in the Community Setting

Thursday, November 12, 2020 from 9:00am – 2:00pm ET: Track 2 - Rare Solid Tumors

  • 9:00am – 11:00am ET: A Critical Update for the Multidisciplinary Team in Differentiating and Tailoring Management of Sarcomas
  • 11:00am – 11:30am ET: Where are we Headed in Thyroid Cancer? New and Emerging Treatment Approaches
  • 11:30am – 12:30pm ET: All About NETs: Disease Pathway, Treatment, and Clinical Trials for GEP-NETs, Pheochromocytoma, and Paragangliomas
  • 12:30pm – 1:30pm ET: Reducing Diagnostic Challenges and Expanding Treatment Options for Advanced GIST
  • 1:30pm – 2:00pm ET: Molecular Profiling and Targeted Therapies Shifting the Paradigm for Cholangiocarcinoma (Bile Duct Cancer)

Enduring Material
The enduring material will be available from October 28, 2020 to October 28, 2021

Estimated Time to Complete
Track 1 - 4 hours
Track 2 - 5 hours
Enduring activity - 9 hours

Disclosures of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Catherine M. Broome, MD

  • Consulting Fees: Alexion, Apellis, Argenx, Sanofi
  • Contracted Research: Alexion, Apellis, Argenx, Sanofi

Steven Horwitz, MD

  • Consulting Fees: ADC Therapeutics, C4 Therapeutics, Celgene, Janssen, Kura Oncology, Kyowa Hakko Kirin, Myeloid Therapeutics, Seattle Genetics, Takeda, Trillium Therapeutics, Verastem, Vividion Therapeutics
  • Contracted Research: ADC Therapeutics, Affimed, Aileron, Celgene, Daiichi Sankyo, Forty Seven, Inc., Kyowa Hakko Kirin, Millennium/Takeda, Portola Pharmaceuticals, Seattle Genetics, Trillium Therapeutics, and Verastem

Ayalew Tefferi, MD has no conflicts of interest to disclose.

Robert J. Kreitman, MD

  • Royalty: Receive royalties from NIH as coinventor on NIH patent for Moxetumomab Pasudotox
  • Receipt of Intellectual Property Rights/Patent Holder: Coinventor on NIH patient for Moxetumomab Pasudotox

Jonathan C. Trent, MD, PhD

  • Consulting Fee: Blueprint, C4 Therapeutics, Daiichi-Sankyo, Deciphera

Lori J. Wirth, MD

  • Consulting Fees: Bayer, Blueprint Medicines, Cue Biopharma, Eisai, Eli Lilly, Exelixis, Genentech, Loxo Oncology, Merck
  • Contracted Research: Ayala, Bayer, Eisai, Eli Lilly, Merck
  • Other DSMC: PDS Biotech

Jonathan Strosberg, MD

  • Consulting Fees: Novartis

Michael C. Heinrich, MD, FACP

  • Royalty: Novartis
  • Consulting Fees: Blueprint Medicine, Deciphera Pharmaceuticals, Novartis
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest: Deciphera Pharmaceuticals

Ghassan Abou-Alfa, MD, MBA

  • Consulting Fees (self): Agios, AstraZeneca, Autem, Bayer, Beigene, Berry Genomics, Debio, Eisai, Eli Lilly, Exelixis, Flatiron, Genentech/Roche, Gilead, Helio, Incyte, Ipsen, Merck, MINA, QED, Redhill, Sillajen, Therabionics, Twoxar, Vector, Yiviva
  • Consulting Fees (spouse): Celgene, CytomX, Loxo, Merck, Silenseed, Sobi, Twoxar
  • Contracted Research (self): Agios, AstraZeneca, Bayer, Berry Genomics, BMS, Casi, Exelixis, Genoscience, Incyte, Polaris, Puma, QED, Sillajen
  • Contracted Research (spouse): ActaBiologica, AstraZeneca, BMS, Celgene, Genentech/Roche, Halozyme, Mabvax, Silenseed

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Tariqa Ackbarali, Medical Director, PlatformQ Health Education, LLC, has no conflicts of interest to disclose.

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Alissa Yost, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unapproved/Off Label Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation

There are no fees to participate in this activity. To participate in the activity, go to www.OMedLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test. For Pharmacists: Upon receipt of the completed activity evaluation form credit will be submitted to the NABP CPE Monitor Service. Pharmacists will need to provide their National Association of Boards of Pharmacy (NABP) e-Profile ID and date of birth (MMDD) to ensure the data is submitted to the ACPE and NABP properly. If you need to obtain your NABP e-Profile, please visit www.nabp.net.

Hardware/Software Requirements

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Accreditation Support:
Please contact the Postgraduate Institute for Medicine at www.pimed.com

Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com

PlatformQ Health Privacy Policy:

By clicking “Start Activity” you are agreeing to PlatformQ Health’s privacy policy. PlatformQ Health takes your privacy very seriously. The full Privacy Policy found here describes (i) the types of information we collect from you when you visit our Site; (ii) how we use the information we collect; (iii) with whom and why we share it; and (iv) the choices we offer regarding our use of the information. We also describe how to contact us about our privacy practices.

Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.

In plain English, here is what we affirm:

  • You can change your registration profile at any time from our “Profile” page
  • To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at support@PlatformQHealth.com
  • You can end your association with PlatformQ Health at any time
  • PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
  • EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting support@platformqhealth.com with the subject line “Data Request”

You acknowledge and agree that by beginning this activity, you have affirmatively agreed to this Privacy Policy and consented to receiving electronic messages in conformance with this Privacy Policy. Please read the full privacy policy located at: www.platformqhealth.com/privacy-policy/